Dr. Pautier on the Rationale for the LMS-02 Trial in Soft Tissue Sarcoma

Patricia Pautier, MD, head of the Medical Day Hospital Unit at the Institut Gustave Roussy Cancer Campus, discusses the rationale for the phase 2 LMS-02 trial in ​uterine and soft tissue leiomyosarcoma. 

Soft tissue sarcomas are rare and ​relatively heterogeneous malignancies, Pautier explains. ​Some subtypes, such as leiomyosarcoma, are associated with poor prognosis​ and therefore, have limited studies dedicated to ​them.

The LMS-02 trial evaluated the safety and efficacy of doxorubicin in combination with trabectedin in patients with metastatic ​or ​advanced uterine and soft tissue leiomyosarcoma.

To date, the ​first-line standard of care for this patient population is doxorubicin alone, Pautier concludes.